Helus Pharma Inc. has announced promising results from its Phase 3 clinical study of HLP003, a novel treatment for major depressive disorder (MDD). The study, named APPROACH, demonstrated statistically significant improvements in depression symptoms, which could significantly impact treatment options for patients suffering from this condition.

This development is crucial for Helus Pharma as it seeks to establish a foothold in the competitive pharmaceutical preparations sector. The results suggest that HLP003 may offer a new, effective adjunctive treatment for those who do not respond adequately to existing therapies.

Background

Helus Pharma Inc. is a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists aimed at improving treatment outcomes for mental health conditions. The company is incorporated in Canada and trades under the ticker HELP on the Nasdaq. Its recent filings include multiple 6-K forms, with the latest dated November 16, 2026, and an accession number of 0000950103-26-017524.

What the Filing Says

The SEC filing reveals that HLP003 achieved a -7.6 point placebo-adjusted change from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS) at Week 6, with a p-value of less than 0.0001. The results indicate that improvements were noted as early as Day 2 and were maintained throughout the study.

Impact

This breakthrough could affect various stakeholders, including patients suffering from MDD, healthcare providers, and the broader pharmaceutical industry. The positive results may lead to increased interest in adjunctive treatments for depression, particularly for those who have not found relief with traditional antidepressants.

What's Next

Helus Pharma plans to continue its momentum towards regulatory approval for HLP003 and is expected to report results from its ongoing EMBRACE trial in the fourth quarter of 2027. The filing does not specify any immediate next steps beyond these developments.